Connect your AI

ADMA Biologics ADMA Long-term debt, gross

Long-term debt, gross at other companies

BlackstoneBX

$13.28B+6.6%

Mirion TechnologiesMIR

$443.5M—

RBC BearingsRBC

400,000,000%—

MSCIMSCI

$6.45B+41.1%

Bread Financial HoldingsBFH

$837M-34.9%

HalliburtonHAL

$7.07B-1.3%

Other financials

Income statement

Revenue$114.5M-0.3%

Gross profit$80.8M+32.2%

Operating income$58.3M+67.1%

Net income$45.3M+68.5%

EPS (diluted)$0.19+72.7%

Balance sheet

Cash & equivalents$138.2M+92.9%

Total debt$204.4M+2,055%

Total equity$390.3M+4.5%

Total assets$665.2M+30.3%

Cash flow

Operating cash flow$58.2M+396%

CapEx$2.5M-45.9%

Free cash flow$55.7M+329%

Valuation

Market cap$2.01B-54.5%

Enterprise value$2.08B-52.5%

P/E12.2×-9.2×

P/S4×-5.7×

Profitability

Gross margin61.3%+8.7pp

Operating margin42.1%+9.0pp

Net margin32.4%-12.6pp

FCF margin21.2%+1.4pp

Returns & leverage

Return on equity43.3%-35.2pp

Debt / equity0.5×+0.5×

Current ratio7×+0.4×

Where this comes from

Reported directly by ADMA Biologics in its filing.

Tagged under the XBRL concept us-gaap:DebtInstrumentCarryingAmount.

The official record: ADMA Biologics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about ADMA Biologics's long-term debt, gross.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is ADMA Biologics's long-term debt, gross?: ADMA Biologics (ADMA) reported long-term debt, gross of $198.59M in Q1 2026.